Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
The Laryngoscope|August 4, 2006
Transoral robotic surgery (TORS) for base of tongue neoplasmsBert W O'Malley, Gregory S Weinstein, Wendy Snyder, et al.The Annals of Otology, Rhinology, and Laryngology|February 20, 2007
Transoral robotic surgery: supraglottic partial laryngectomyGregory S Weinstein, Bert W O'Malley, Wendy Snyder, et al.Archives of Otolaryngology--Head & Neck Surgery|December 19, 2007
Transoral robotic surgery: radical tonsillectomyGregory S Weinstein, Bert W O'Malley, Wendy Snyder, et al.Transcultural Psychiatry|May 29, 2003
Pre-migration trauma and HIV-risk behaviorJennifer Steel, Claes Herlitz, Jesse Matthews, et al.European Journal of Cancer (Oxford, England : 1990)|June 13, 2024
Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115Caroline Robert, Brian Gastman, Helen Gogas, et al.Human Brain Mapping|November 30, 2006
Hemodynamic responses in neural circuitries for detection of visual target and novelty: An event-related fMRI studyRuben C Gur, Bruce I Turetsky, James Loughead, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b StudyKevin J Harrington, Anthony Kong, Nicolas Mach, et al.The American Journal of Psychiatry|March 3, 2007
Visual attention circuitry in schizophrenia investigated with oddball event-related functional magnetic resonance imagingRaquel E Gur, Bruce I Turetsky, James Loughead, et al.Journal for Immunotherapy of Cancer|May 4, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trialJason A Chesney, Igor Puzanov, Frances A Collichio, et al.European Journal of Cancer (Oxford, England : 1990)|July 19, 2024
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLCMaximilian J Hochmair, Karim Vermaelen, Giannis Mountzios, et al.Pageof 2